Edition:
United States

People: Opexa Therapeutics Inc (OPXA.PH)

OPXA.PH on Philadelphia Stock Exchange

0.74USD
18 Aug 2017
Change (% chg)

-- (--)
Prev Close
$0.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,057
52-wk High
$4.82
52-wk Low
$0.56

Warma, Neil 

Mr. Neil K. Warma is President, Chief Executive Officer, Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Director of the Comapany. He has served as President and Chief Executive Officer since June 2008 and as a Director since September 2008. He also previously served as our Acting Chief Financial Officer from March 2009 to August 2012. From July 2004 to September 2007, Mr. Warma served as president and chief executive officer of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company. From 2000 to 2003 Mr. Warma was co-founder and president of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies. From 1992 to 2000, Mr. Warma held senior positions of increasing responsibility at Novartis Pharmaceuticals (previously Ciba-Geigy Ltd.) at its corporate headquarters in Basel, Switzerland. While at Novartis, Mr. Warma served as the Head of International Pharma Policy & Advocacy and in senior management within global marketing where he worked on the international launch of a gastrointestinal product. Mr. Warma obtained an honors degree specializing in Neuroscience from the University of Toronto and an International M.B.A. from the Schulich School of Management at York University in Toronto. As our President and Chief Executive Officer, Mr. Warma is directly involved in all aspects of our operations. He has extensive experience in corporate business development within the biopharmaceutical industry, in addition to executive leadership and management experience.

Basic Compensation

Total Annual Compensation, USD 416,625
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 92,112
Fiscal Year Total, USD 508,737

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --